LDS/Medical Tests/C4d Complement Activation Fragment, Plasma

C4d Complement Activation Fragment, Plasma

C4d is a stable split product of complement component C4 generated during activation of the classical and lectin complement pathways. Upon activation, C4d binds covalently to nearby tissues and circulating surfaces, making it a durable marker of complement activation. Because of this stability, C4d has become an important diagnostic and prognostic biomarker in immune-mediated kidney diseases and transplantation.

C4d was first recognized as a hallmark of antibody-mediated rejection (AMR) in kidney allografts, where deposition in peritubular capillaries reflects antibody-mediated endothelial injury. Its incorporation into the Banff classification significantly advanced transplant pathology by providing objective evidence of humoral rejection. Although recent Banff updates acknowledge C4d-negative AMR, C4d positivity remains a strong indicator of classical or lectin pathway activation and continues to guide immunosuppressive management. Plasma C4d levels have been shown to correlate with tissue deposition and may serve as a non-invasive marker for monitoring graft injury and response to therapy.

Beyond transplantation, C4d plays an increasingly recognized role in native kidney diseases. In IgA nephropathy, glomerular and tubular C4d deposition is associated with higher proteinuria, more aggressive histologic lesions, and worse renal outcomes in both adult and pediatric patients. C4d positivity in this setting likely reflects lectin pathway activation and identifies patients at higher risk for progression. In membranoproliferative glomerulonephritis, C4d helps distinguish immune complex–mediated disease, which typically demonstrates strong C4d staining, from complement-mediated C3 glomerulopathy, which is usually C4d-negative. This distinction is clinically important because the underlying pathophysiology and treatment strategies differ significantly.

In lupus nephritis, widespread C4d deposition in glomeruli, peritubular capillaries, and tubular basement membranes correlate with disease activity, relapse risk, and microvascular injury. Similar associations have been observed in pediatric lupus nephritis, where C4d levels correlate with proteinuria, hypertension, and histologic severity. In membranous nephropathy, diffuse continuous C4d staining favors primary disease, whereas segmental or discontinuous staining suggests secondary etiologies. Measurement of circulating C4d therefore provides valuable adjunctive information when evaluating immune-mediated renal disease and complement activation.

  • As an aid in the diagnosis and monitoring of antibody-mediated rejection (AMR) in kidney transplants
  • As an aid in the diagnosis and monitoring complement-mediated glomerulopathies, including lupus nephritis, IgA nephropathy, and immune complex–mediated MPGN
Increased levels are observed in antibody-mediated rejection of solid organ transplants, immune complex–mediated glomerulonephritis, active lupus nephritis, IgA nephropathy with lectin pathway activation, post-infectious glomerulonephritis, and other autoimmune or inflammatory states associated with complement activation. Decreased levels may be seen in advanced disease with complement consumption or in congenital complement deficiencies. Results should always be interpreted in conjunction with clinical findings, histopathology, and other complement markers such as C3 and C4.

16 to 48 mg/dL

Enzyme-linked immunosorbent assay (ELISA).

Plasma, EDTA or Citrate.

Stability

  • Ambient: 2-5 days
  • Refrigerated: 7 days
  • Frozen: 3 months
Kidney biopsy, urinalysis, creatinine clearance, protein creatinine ratio, renal function panel, Angiotensin converting enzyme, Anti-streptolysin O, C3, C4, CBC, ANCA, comprehensive metabolic panel, BUN, urine culture.
1 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login